[go: up one dir, main page]

WO2018068565A1 - Application d'albiflorine dans la production de produits destinés à améliorer la fonction du système mélatonine - Google Patents

Application d'albiflorine dans la production de produits destinés à améliorer la fonction du système mélatonine Download PDF

Info

Publication number
WO2018068565A1
WO2018068565A1 PCT/CN2017/095985 CN2017095985W WO2018068565A1 WO 2018068565 A1 WO2018068565 A1 WO 2018068565A1 CN 2017095985 W CN2017095985 W CN 2017095985W WO 2018068565 A1 WO2018068565 A1 WO 2018068565A1
Authority
WO
WIPO (PCT)
Prior art keywords
melatonin
disease
paeoniflorin
improving
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/095985
Other languages
English (en)
Chinese (zh)
Inventor
张作光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2018068565A1 publication Critical patent/WO2018068565A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention belongs to the field of medicine, relates to the use of paeoniflorin (Albiflorin), and more particularly to the use of paeoniflorin in the preparation of a product for improving the function of the melatonin system, in particular, it is prepared for prevention and/or treatment.
  • paeoniflorin Albiflorin
  • Melatonin N-acetyl-5-methoxytryptamine
  • Melatonin is a hormone mainly synthesized and secreted by the pineal gland, and is mainly synthesized by tryptophan and S-adenosylmethionine.
  • Melatonin regulates mammalian circadian rhythms and reproductive functions, and is a lipophilic hormone that is widely distributed in the nervous system, blood, and surrounding tissues of mammals. Melatonin exerts its biological effects by interacting with specific melatonin receptors.
  • the circadian rhythm is regulated by receptors present in the suprachiasmatic nucleus, and natural sleep is brought about by hypothermia or by regulating nerve and endocrine functions.
  • the secretion of melatonin is inhibited by nighttime illumination, which is the cause of circadian rhythm disorders or accompanying sleep disorders.
  • the secretion of melatonin decreases with ageing and is the main cause of sleep disorders in the elderly.
  • melatonin has a wide range of effects on the body, including biological rhythm, hormone secretion, and neuro-endocrine- Immune system regulation, stress response, aging process, tumorigenesis, as well as free radical damage, elevated blood sugar, sedation, sleep, anti-inflammatory, analgesic and many other aspects.
  • melatonin has anti-cancer functions, and many recent studies have reported that melatonin can inhibit the growth and proliferation of a variety of tumor cells including breast cancer, ovarian cancer, endometrial cancer, melanoma, prostate tumors, and intestinal tumors. .
  • Melatonin is in mental disorders (bipolar, depression and anxiety disorders, schizophrenia, epilepsy and seizures), neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, Treatment of muscle sclerosis) and neuroendocrine disorders (peptic ulcers, psoriasis) may be beneficial.
  • PD Parkinson's disease
  • melatonin has significant neuroprotective and anti-inflammatory functions and can be used as a neuroprotective drug after stroke.
  • the neuroprotective effect of melatonin is believed to be achieved through its antioxidant and free radical scavenging functions.
  • the object of the present invention is to provide a new use of bismuth lactone (Albiflorin) as a new product for improving the function of melatonin system, which can simultaneously promote endogenous melatonin in view of the deficiencies of the prior art.
  • Secreting increasing the concentration of melatonin receptors in the body and/or increasing the activity of melatonin receptors in the organism, and thus can be used to prevent and/or treat sub-health states caused by melatonin system dysfunction and/or disease.
  • the present invention also provides a method of improving the function of a melatonin system in a living body.
  • Paeoniflorin a product that improves the function of the melatonin system, can be used to prepare drugs, foods, health supplements, food additives or nutritional supplements for the prevention and/or treatment of sub-health states, diseases caused by melatonin system dysfunction.
  • the sub-health state caused by dysfunction of the melatonin system is selected from one or more of a biological rhythm disorder sleep disorder, an elderly sleep disorder, an affective disorder, a cognitive dysfunction, and an immune system dysfunction, and the disease is selected from insomnia.
  • Albiflorin is a monoterpenoid compound with a molecular formula of C 23 H 28 O 11 and a molecular weight of 480.46.
  • the molecular structure is as shown in the following formula. It is a natural active substance derived from the genus Ranunculaceae ( Paeonia lactiflora Pall) or the root of Paeonia veitchii Lynch, the root of P. suffrsticosa Andrz.
  • the pharmaceutically acceptable salt of the compound of the formula (I) may be selected from the group consisting of citrate, hydrochloride, sulfate, malate, tartrate, citrate and phosphoric acid. One or more of the salts.
  • the present invention discloses a paeoniflorin or a pharmaceutically acceptable salt thereof, or an extract comprising paeoniflorin or a pharmaceutically acceptable salt thereof as an endogenous melatonin secretion promoter and/or melatonin
  • the receptor agonist can improve the function of the human melatonin system by promoting endogenous melatonin secretion and increasing the concentration and activity of the melatonin receptor MT1; the human melatonin system function promoting agent paeoni lactone of the present invention Glycosides or pharmaceutically acceptable salts thereof, or extracts comprising paeoniflorin or a pharmaceutically acceptable salt thereof, can promote dopamine, which is closely related to biorhythm regulation and sleep, by increasing serotonin content in rat hippocampus, Secretion of melatonin and melatonin receptors, improve and treat sub-health states and diseases caused by melatonin system dysfunction, including biorhythm disorder sleep disorders, senile sleep disorders, cognitive
  • the present invention discloses a paeoniflorin or a pharmaceutically acceptable salt thereof, or an extract comprising paeoniflorin or a pharmaceutically acceptable salt thereof, by modulating N-acetyl serotonin-O-methyltransferase (ASMT) promotes endogenous melatonin secretion and affects the function of the melatonin system by increasing the activity and content of melatonin receptor (MT1).
  • ASMT N-acetyl serotonin-O-methyltransferase
  • the present invention provides a use of a paeoniflorin or a pharmaceutically acceptable salt thereof, or an extract comprising a paeoniflorin or a pharmaceutically acceptable salt thereof, for the manufacture of a product for improving the function of a melatonin system ;
  • the product for improving the function of the melatonin system is an endogenous melatonin secretion promoter and/or a melatonin receptor agonist, wherein the melatonin receptor agonist enhances melanin in vivo The concentration of the receptor and/or increase the activity of the melatonin receptor in the organism;
  • the product that improves the function of the melatonin system is provided in the form of a drug, food, health supplement, food additive or nutritional supplement.
  • the melatonin system function is to prevent and/or treat a sub-health state and/or disease caused by melatonin system dysfunction;
  • the sub-health state is selected from one or more of, but not limited to, one of a biological rhythm disorder sleep disorder, an elderly sleep disorder, an affective disorder, a cognitive dysfunction, and an immune system dysfunction.
  • the disease is selected from one or more of insomnia, depression, anxiety, Alzheimer's disease, and Parkinson's disease, but is not limited to these symptoms.
  • the invention provides a method for improving the function of a melatonin system, the method comprising administering to a subject an effective amount of a paeoniflorin or a pharmaceutically acceptable salt thereof, or comprising a peony An extract of a lactone or a pharmaceutically acceptable salt thereof;
  • said improving melatonin system functions to promote endogenous melatonin secretion and/or activate melatonin receptor, wherein said activation of melatonin receptor is to increase melatonin receptor concentration and / Or increase the activity of melatonin receptors.
  • the melatonin system function is to prevent and/or treat a sub-health state and/or disease caused by melatonin system dysfunction;
  • the sub-health state is selected from one or more of a biological rhythm disorder sleep disorder, an elderly sleep disorder, an affective disorder, a cognitive dysfunction, and an immune system dysfunction; but is not limited to these symptoms.
  • the disease is selected from one or more of insomnia, depression, anxiety, Alzheimer's disease, and Parkinson's disease, but is not limited to these symptoms.
  • the present invention provides a composition for improving the function of a melatonin system comprising a paeoniflorin or a pharmaceutically acceptable salt thereof, or a paeoni lactone or a pharmaceutically acceptable thereof Salt extract;
  • said improving melatonin system functions to promote endogenous melatonin secretion and/or activate melatonin receptor, wherein said activation of melatonin receptor is to increase melatonin receptor concentration and / Or increase the activity of melatonin receptors.
  • the composition for improving the function of the melatonin system is a medicine, a food, a health supplement, a food additive or a nutritional supplement.
  • the melatonin system function is to prevent and/or treat a sub-health state and/or disease caused by melatonin system dysfunction;
  • the sub-health state is selected from one or more of, but not limited to, one of a biological rhythm disorder sleep disorder, an elderly sleep disorder, an affective disorder, a cognitive dysfunction, and an immune system dysfunction.
  • the disease is selected from one or more of insomnia, depression, anxiety, Alzheimer's disease, and Parkinson's disease, but is not limited to these symptoms.
  • the present invention provides a paeoniflorin or a pharmaceutically acceptable salt thereof for improving the function of a melatonin system, or an extract comprising a paeoniflorin or a pharmaceutically acceptable salt thereof;
  • said improving melatonin system functions to promote endogenous melatonin secretion and/or activate melatonin receptor, wherein said activation of melatonin receptor is to increase melatonin receptor concentration and / Or increase the activity of melatonin receptors.
  • said improving the melatonin system function is to prevent and/or treat a sub-health state and/or disease caused by melatonin system dysfunction;
  • the sub-health state is selected from the group consisting of a biological rhythm disorder sleep disorder, an elderly sleep disorder, One or more of affective disorder, cognitive dysfunction, and immune system dysfunction, but are not limited to these symptoms.
  • the disease is selected from one or more of insomnia, depression, anxiety, Alzheimer's disease, and Parkinson's disease, but is not limited to these symptoms.
  • the present invention promotes human melatonin-melatonin receptor by a multi-target multi-target by a paeoniflorin or a pharmaceutically acceptable salt thereof, or an extract containing paeoniflorin or a pharmaceutically acceptable salt thereof
  • the present invention has the following advantages:
  • the present invention promotes endogenous melatonin secretion and enhances melatonin system function by activating N-acetyl serotonin-O-methyltransferase (ASMT). Therefore, the present invention compensates for the defects and deficiencies in the regulation of the function of the endogenous melatonin system by the prior art using exogenous melatonin, and avoids the possible tolerance of long-term ingestion of exogenous melatonin. Defects such as dependence and efficacy instability.
  • ASMT N-acetyl serotonin-O-methyltransferase
  • the invention not only promotes the secretion of endogenous melatonin, but also increases the activity and content of melatonin receptor (MT1). Therefore, the present invention compensates for the inability of the exogenous melatonin to improve melatonin receptor secretion dysfunction by regulating the multi-target multi-target of the melatonin system and enhancing the function of the human melatonin system. Defects and deficiencies.
  • the invention has the dual functions of anti-depression and improving sleep, and compensates for the side effects of SSRI affecting sleep, such as Baiyou solution of the first-line antidepressant drugs, and increases the patient's compliance and tolerance to drugs.
  • the present invention increases the function of the melatonin system, increases slow wave sleep (SWS), improves the quality of deep sleep, improves sleep disorders, and does not produce benzodiazepines, barbituric sleeping pills, addiction, influence recognition Know the side effects such as function.
  • SWS slow wave sleep
  • Figure 1 shows that the paeoniflorin of the present invention improves depression by down-regulating kynuric acid and up-regulating the serotonin-melatonin metabolism pathway.
  • Fig. 2 shows that the paeoniflorin of the present invention regulates biological rhythm, improves depression, and improves sleep by improving dopamine and melatonin.
  • Figure 3 is a graph showing the effect of the paeoniflorin on the content of the rate-limiting enzyme N-acetyl serotonin-O-methyltransferase (ASMT) in the melatonin synthesis pathway in the hippocampus of chronically stressed rats.
  • ASMT N-acetyl serotonin-O-methyltransferase
  • Figure 4 is a graph showing the effect of paeoniflorin on the content of melatonin receptor (MT1) in the hippocampus of chronically stressed rats.
  • Example 1 Effect of paeoniflorin on melatonin system function in CUMS rats
  • Paeoniflorin can significantly increase the secretion of dopamine and melatonin in the hippocampus of chronic stress rats, which is closely related to biological rhythm and sleep, and thus play a role in improving sleep, see Figure 2.
  • the final step in the synthesis of melatonin metabolism is the conversion of N-acetyl serotonin to melatonin by methylation.
  • This step is performed by N-acetyl serotonin-O-methyltransferase (ASMT), so ASMT is the rate-limiting enzyme in the synthesis of melatonin in humans.
  • ASMT N-acetyl serotonin-O-methyltransferase
  • the content of ASMT in hippocampus of rats in chronic stress group (model group) was decreased (P ⁇ 0.01), and paeoniflorin could significantly increase the content of ASMT (P ⁇ 0.01), and restore and promote the synthesis of endogenous melatonin. See Table 1 below and Figure 3, wherein Figure 3 uses the Western blot method to determine the amount of N-acetyl serotonin-O-methyltransferase.
  • paeoniflorin has a function of promoting endogenous melatonin and increasing secretion of melatonin receptor through a new generation of targeted metabolomics research; according to this function, paeoniflorin can be used And extracts and compositions containing paeoniflorin are developed into foods, health supplements, food additives or nutritional supplements capable of regulating and improving endogenous melatonin, prepared for antidepressant, anti-aging, improving sleep and improving Cognitive function, drugs that delay and prevent Alzheimer's disease.
  • Example 3 Effect of paeoniflorin on learning and memory function in mice with scopolamine dementia
  • the water maze test was performed to find the swimming time (ie, escape latency) and swimming distance of the mouse as the observation index after entering the water.
  • the experimental results showed that compared with the model group, the escape latency of the paeoniflorin group was significantly shorter on the 4th and 5th day (P ⁇ 0.05), as shown in Table 5; compared with the model group, the paeoniflorin group 4, 5 The swimming distance of the day was shortened (P ⁇ 0.05), see Table 6.
  • the results of this experiment indicate that paeoniflorin can significantly improve the learning and memory ability of mice with dementia induced by scopolamine.
  • the test group animals were given three doses of paeoniflorin, and the control group was given a sleep phenomenon after the same volume of solvent. Sleep disappears as an indicator of righting reflex. When the mouse is placed in the back position, it can immediately correct the position. If it can't be corrected for more than 30 seconds, it means that the righting reflex disappears and goes to sleep. The recovery of righting reflex was the awakening of the animal, and the righting reflex disappeared until the recovery time was the animal's sleep time. The number of sleeping animals and the sleep time of the blank control group and the paeoniflorin group were recorded. The experimental results are shown in Table 7:
  • the paeoniflorin has no direct sleep effect on experimental animals.
  • Table 8 suggests that paeoniflorin, which is higher than the 14 mg/kg bw dose, can prolong the threshold time of pentobarbital sodium-induced sleep time in mice, and is significantly different from the sleep time of the control group (p ⁇ 0.05).
  • the animals were given a blank control and different concentrations of paeoniflorin at the last 10 minutes before the peak effect.
  • the animals in each group were intraperitoneally injected with the maximum subthreshold hypnotic dose of pentobarbital sodium (30 mg/kg BW), and the number of sleeping animals in 30 minutes was recorded. The righting reflection disappears for more than 1 minute).
  • the experiment should be carried out in a quiet environment of 24-25 °C.
  • Table 9 The experimental results are shown in Table 9:
  • Table 9 shows that the sleep incidence of the mice in each dose group caused by paeoniflorin to the subthreshold dose of pentobarbital was higher than that of the control group, and there was a significant difference compared with the control group (p ⁇ 0.01).
  • paeoniflorin can shorten the sleep latency of experimental mice induced by barbital sodium.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une application d'albiflorine ou de son sel de qualité pharmaceutique dans la production de produits destinés à améliorer la fonction du système mélatonine humain. L'albiflorine ou son sel de qualité pharmaceutique, en tant que promoteur de sécrétion de mélatonine endogène et agoniste du récepteur de la mélatonine, peut être utilisé dans la production de médicaments, d'aliments, de suppléments de santé, d'additifs alimentaires, ou de suppléments nutritionnels qui améliorent et traitent des états de santé sous-optimale et/ou des maladies provoqués par un dysfonctionnement du système mélatonine ; les états de santé sous-optimale sont un ou plusieurs états parmi des troubles de l'alternance veille-sommeil liés au rythme circadien, la dyssomnie sénile, les troubles affectifs, les troubles cognitifs, et les troubles du système immunitaire ; les maladies sont une ou plusieurs maladies parmi la dépression, l'anxiété, la maladie d'Alzheimer et la maladie de Parkinson.
PCT/CN2017/095985 2016-10-11 2017-08-04 Application d'albiflorine dans la production de produits destinés à améliorer la fonction du système mélatonine Ceased WO2018068565A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610884496 2016-10-11
CN201610884496.2 2016-10-11

Publications (1)

Publication Number Publication Date
WO2018068565A1 true WO2018068565A1 (fr) 2018-04-19

Family

ID=60436432

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/095985 Ceased WO2018068565A1 (fr) 2016-10-11 2017-08-04 Application d'albiflorine dans la production de produits destinés à améliorer la fonction du système mélatonine

Country Status (2)

Country Link
CN (1) CN107412244A (fr)
WO (1) WO2018068565A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020168760A1 (fr) * 2019-02-21 2020-08-27 张作光 Utilisation d'albiflorine dans la préparation de médicaments pour le traitement rapide de la dépression
CN114886903B (zh) * 2022-05-09 2024-02-02 黑龙江中医药大学 一种用于治疗失眠的药物及其用途
CN116855531B (zh) * 2023-08-24 2023-12-19 扬州大学 牡丹PsASMT基因或其载体在改变植物花色中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010133015A1 (fr) * 2009-05-21 2010-11-25 陈婷 Composition pharmaceutique destinée à traiter la dépression et procédé de préparation et utilisation de celle-ci
WO2011003226A1 (fr) * 2009-07-10 2011-01-13 陈婷 Composition pharmaceutique destinée au traitement de la dépression, sa méthode de préparation et son utilisation
WO2011047576A1 (fr) * 2009-10-20 2011-04-28 Zhang Zuoguang Utilisation d'albiflorine en tant qu'antidépresseur
WO2011088715A1 (fr) * 2010-01-19 2011-07-28 Zhang Zuoguang Utilisation d'albiflorine pour le traitement de la maladie de parkinson
WO2012068958A1 (fr) * 2010-11-25 2012-05-31 Zhang Zuoguang Utilisation de l'albiflorine ou d'un métabolite de celle-ci dans la lutte contre l'anxiété et pour l'amélioration de troubles du sommeil
WO2016134563A1 (fr) * 2015-02-26 2016-09-01 张作光 Albiflorine ou son sel pharmaceutiquement acceptable et/ou son utilisation pour le traitement du syndrome du côlon irritable

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010133015A1 (fr) * 2009-05-21 2010-11-25 陈婷 Composition pharmaceutique destinée à traiter la dépression et procédé de préparation et utilisation de celle-ci
WO2011003226A1 (fr) * 2009-07-10 2011-01-13 陈婷 Composition pharmaceutique destinée au traitement de la dépression, sa méthode de préparation et son utilisation
WO2011047576A1 (fr) * 2009-10-20 2011-04-28 Zhang Zuoguang Utilisation d'albiflorine en tant qu'antidépresseur
WO2011088715A1 (fr) * 2010-01-19 2011-07-28 Zhang Zuoguang Utilisation d'albiflorine pour le traitement de la maladie de parkinson
WO2012068958A1 (fr) * 2010-11-25 2012-05-31 Zhang Zuoguang Utilisation de l'albiflorine ou d'un métabolite de celle-ci dans la lutte contre l'anxiété et pour l'amélioration de troubles du sommeil
WO2016134563A1 (fr) * 2015-02-26 2016-09-01 张作光 Albiflorine ou son sel pharmaceutiquement acceptable et/ou son utilisation pour le traitement du syndrome du côlon irritable

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAN, RONG: "Neuroprotective Effects of Paeoniflorin and Albiflorin, Two Major Constituents of JD-30", MEDICINE & PUBLIC HEALTH, CHINA DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, 15 February 2015 (2015-02-15), pages 057 - 9 *

Also Published As

Publication number Publication date
CN107412244A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
Zhang et al. Sesamol alleviates chronic intermittent hypoxia-induced cognitive deficits via inhibiting oxidative stress and inflammation in rats
CN102274227B (zh) 粉防己碱在制备预防和/或治疗抑郁症药物中的应用
WO2006013792A1 (fr) Dérivé de benzylisoquinoléine - ou dérivé bisbenzylisoquinoléine - contenant un agent psychotrope, analgésique et/ou antiphlogistique, et aliment de santé.
US20140271890A1 (en) Controlled-release pharmaceutical composition
Salama et al. Experimental and therapeutic trials of amygdalin
WO2018068566A1 (fr) Application de l'albiflorine dans la production de produits destinée à améliorer la fonction du système de la flore intestinale
CN101791314B (zh) 藏红花素在制备催眠类药物中的用途
WO2018068565A1 (fr) Application d'albiflorine dans la production de produits destinés à améliorer la fonction du système mélatonine
CN104667283B (zh) 一种治疗血脂异常和动脉粥样硬化的复方药物组合
EP2094254B1 (fr) Traitement de la cachexie
Wang et al. Caffeine: a potential mechanism for anti-obesity
US20190247355A1 (en) Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone ester, and other ketonic sources
WO2016134563A1 (fr) Albiflorine ou son sel pharmaceutiquement acceptable et/ou son utilisation pour le traitement du syndrome du côlon irritable
CN114209739B (zh) 一种白头翁提取物在制备治疗抗抑郁药物上的应用
WO2018126673A1 (fr) Application d'albiflorine à titre d'inhibiteur de l'indoléamine 2,3-dioxygénase (ido)
CN103989711A (zh) 一种含褪黑激素的保健制剂及其制备方法
Amancio-dos-Santos et al. Tianeptine facilitates spreading depression in well-nourished and early-malnourished adult rats
US12329774B2 (en) Method and composition for enhancing the quality and benefits of sleep
CN101933963A (zh) 一种治疗头痛的鼻用原位凝胶剂
CN102631397B (zh) 一种改善脑部血液循环的中药组合物及其制备方法
KR101783306B1 (ko) ＰＤＫｓ 억제제를 유효성분으로 함유하는 알러지성 질환의 예방 또는 치료용 약학적 조성물
Pyatigorskaya et al. A Scientific Methodology for Expansion of Anti-Parkinson Drug Product Range
CN102743367A (zh) 路路通鞣质单体的用途
US11464756B1 (en) Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
CN110420209B (zh) 一种治疗糖尿病周围神经痛的药物组合物及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17860780

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17860780

Country of ref document: EP

Kind code of ref document: A1